Free Trial

Aerovate Therapeutics (AVTE) Competitors

Aerovate Therapeutics logo
$10.45 -0.69 (-6.19%)
As of 07/7/2025

AVTE vs. PAHC, WVE, ELVN, VERV, NTLA, COLL, AKBA, SYRE, MLYS, and AVDL

Should you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Phibro Animal Health (PAHC), WAVE Life Sciences (WVE), Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), Intellia Therapeutics (NTLA), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry.

Aerovate Therapeutics vs. Its Competitors

Phibro Animal Health (NASDAQ:PAHC) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Phibro Animal Health has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phibro Animal Health$1.02B1.20$2.42M$0.7838.78
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70-6.15

In the previous week, Phibro Animal Health had 12 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 12 mentions for Phibro Animal Health and 0 mentions for Aerovate Therapeutics. Phibro Animal Health's average media sentiment score of 0.36 beat Aerovate Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company Overall Sentiment
Phibro Animal Health Neutral
Aerovate Therapeutics Neutral

Phibro Animal Health currently has a consensus price target of $24.40, suggesting a potential downside of 19.34%. Given Phibro Animal Health's stronger consensus rating and higher possible upside, equities research analysts plainly believe Phibro Animal Health is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Phibro Animal Health
2 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.83
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Phibro Animal Health has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Phibro Animal Health has a net margin of 2.68% compared to Aerovate Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 30.51% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Phibro Animal Health2.68% 30.51% 6.89%
Aerovate Therapeutics N/A -90.19%-77.47%

99.3% of Phibro Animal Health shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Phibro Animal Health beats Aerovate Therapeutics on 14 of the 15 factors compared between the two stocks.

Get Aerovate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVTE vs. The Competition

MetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$302.89M$783.33M$5.46B$8.93B
Dividend YieldN/A4.84%5.24%4.04%
P/E Ratio-3.491.3027.0720.17
Price / SalesN/A230.51381.5293.95
Price / CashN/A23.4426.2128.59
Price / Book2.646.138.015.59
Net Income-$75.52M-$27.85M$3.17B$248.41M
7 Day Performance4.60%2.46%3.53%6.17%
1 Month Performance45.34%8.69%2.73%7.83%
1 Year Performance-82.84%8.61%34.10%21.03%

Aerovate Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVTE
Aerovate Therapeutics
N/A$10.45
-6.2%
N/A-80.2%$302.89MN/A-3.4920High Trading Volume
PAHC
Phibro Animal Health
3.6813 of 5 stars
$25.54
-0.5%
$21.80
-14.6%
+77.4%$1.04B$1.02B32.741,940Trending News
Analyst Upgrade
WVE
WAVE Life Sciences
4.4251 of 5 stars
$6.50
-2.5%
$20.50
+215.4%
+29.1%$1.04B$108.30M-7.74240News Coverage
ELVN
Enliven Therapeutics
2.687 of 5 stars
$20.06
-3.0%
$39.60
+97.4%
-12.6%$1.01BN/A-10.4550
VERV
Verve Therapeutics
3.4674 of 5 stars
$11.23
-0.6%
$14.57
+29.8%
+112.6%$1.01B$32.33M-5.32110
NTLA
Intellia Therapeutics
4.7052 of 5 stars
$9.38
-1.9%
$33.37
+255.7%
-55.0%$990.25M$57.88M-1.79600
COLL
Collegium Pharmaceutical
4.2589 of 5 stars
$29.57
-1.2%
$43.75
+48.0%
-4.0%$961.71M$664.28M24.24210News Coverage
Analyst Downgrade
Buyback Announcement
AKBA
Akebia Therapeutics
4.2367 of 5 stars
$3.64
-0.3%
$6.75
+85.4%
+287.9%$958.62M$160.18M-17.33430
SYRE
Spyre Therapeutics
1.3394 of 5 stars
$14.97
-1.6%
$53.40
+256.7%
-40.0%$917.39M$890K-3.9773
MLYS
Mineralys Therapeutics
2.1521 of 5 stars
$13.53
-1.3%
$32.25
+138.4%
+8.8%$893.55MN/A-3.6328
AVDL
Avadel Pharmaceuticals
2.4432 of 5 stars
$8.85
-3.8%
$18.17
+105.3%
-39.9%$890M$169.12M-32.7870

Related Companies and Tools


This page (NASDAQ:AVTE) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners